Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer
Sponsor: ECOG-ACRIN Cancer Research Group
A PHASE2 clinical study on Gastric Cancer, this trial is completed. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 8 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Aug 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Atlanta, United States, Boston, United States, Cedar Rapids, United States, Chicago, United States, Cleveland, United States, Denver, United States, Evanston, United States, Indianapolis, United States, Kalamazoo, United States and 16 more location s